A Competing-Risk Model Based on the Life Table Procedure in Epidemiological Studies

1977 ◽  
Vol 6 (2) ◽  
pp. 153-159 ◽  
Author(s):  
OTTO WONG
Keyword(s):  
Life Table ◽  
Risk Model ◽  
Epidemiological Studies ◽  
Competing Risk ◽  
Competing Risk Model ◽  
Model Based

Gout as a risk factor for acute myocardial infarction: evidence from competing risk model analysis

2021 ◽  
pp. jim-2020-001714
Author(s):  
Chia-Luen Huang ◽  
Tai-Wen Wang ◽  
Yong-Chen Chen ◽  
Je-Ming Hu ◽  
Po-Ming Ku ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Risk Model ◽  
Epidemiological Studies ◽  
Competing Risk ◽  
Study Cohort ◽  
Research Database ◽  
Competing Risk Model ◽  
Increased Risk ◽  
Future Work

Chronic inflammation, a hallmark of gout, is implicated in the pathogenesis of atherosclerosis. Thus, in theory, gout can be expected to increase the risk of acute myocardial infarction (AMI). Yet, results from several epidemiological studies have been inconclusive. A retrospective cohort study was conducted using the National Health Insurance Research Database of Taiwan dated from 2000 to 2013. The study cohort comprised 3581 patients with gout (the gout cohort) and 14,324 patients without gout (the non-gout cohort). The primary outcome was the incidence of AMI. To estimate the effect of gout on the risk of AMI, the Lunn-McNeil competing risk model was fitted to estimate cause-specific hazard ratios (HRs) and their 95% confidence intervals (CIs). The cumulative incidence of AMI was significantly higher in the gout cohort than in the non-gout cohort, resulting in an adjusted HR of 1.36 (95% CI 1.04 to 2.76). Further, HRs of gout with incident AMI were higher in patients without hypertension, diabetes mellitus, or hyperlipidemia (ranging from 1.63 to 2.09) than in those with each of these comorbidities (ranging from 0.95 to 1.13). The results of this study suggest that patients with gout have an increased risk of AMI. The AMI risk associated with gout was conditional on patients’ cardiovascular risk profile. Future work is needed to confirm these findings.

Expanded renal transplantation: a competing risk model approach

2015 ◽  
Vol 42 (12) ◽  
pp. 2539-2553
Author(s):  
Pablo Martínez-Camblor ◽  
Jacobo de Uña-Álvarez ◽  
Carmen Díaz Corte
Keyword(s):  
Renal Transplantation ◽  
Risk Model ◽  
Competing Risk ◽  
Competing Risk Model ◽  
Model Approach

Abstract P146: Comparative Effectiveness Of Direct Oral Anticoagulants Versus Warfarin Among Medicare Beneficiaries With Atrial Fibrillation

Circulation ◽  
2021 ◽  
Vol 143 (Suppl_1) ◽  
Author(s):  
Shirin Ardeshirrouhanifard ◽  
Huijun An ◽  
Ravi Goyal ◽  
Mukaila Raji ◽  
Caleb Alexander ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Ischemic Stroke ◽  
Cancer Patients ◽  
Risk Model ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Competing Risk ◽  
Secondary Outcome ◽  
Systemic Embolism ◽  
Competing Risk Model

Objective: Post-hoc analysis of three pivotal clinical trials suggests no difference in risk of ischemic stroke or systemic embolism among cancer patients with atrial fibrillation treated with direct oral anticoagulants (DOACs) vs. warfarin. However, these studies were underpowered and also do not reflect the context of real-world use. We compared the effectiveness of DOACs versus warfarin for the risk of stroke or systemic embolism and all-cause death in patients with NVAF. Methods: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data from 2009 to 2016 and included patients aged ≥66 years diagnosed with cancer (breast, bladder, colorectal, esophagus, lung, ovary, kidney, pancreas, prostate, stomach or uterus) and NVAF. We limited the cohort to patients who newly initiated warfarin or DOACs (from 2010 to 2016) with no history of ischemic stroke or systemic embolism. The primary outcome was hospitalization due to ischemic stroke or systemic embolism and the secondary outcome was all-cause death. We used Fine and Gray’s competing risk model, while treating death as a competing risk, to determine the association of oral anticoagulants with the incidence of stroke or systemic embolism. We also adjusted the analysis using inverse probability of treatment weighted (IPTW). Additionally, an IPTW-adjusted Cox proportional hazards regression model was constructed for all-cause death. Results: Of 1,028,784 patients with cancer, 158,744 (15.4%) were diagnosed with atrial fibrillation. After applying all inclusion criteria, the final study cohort included 7,334 cancer patients diagnosed with incident NVAF who newly initiated warfarin or DOACs, of which 3,194 (43.6%) used warfarin and 4,140 (56.4%) used DOACs. The unadjusted rate of stroke or systemic embolism was similar among warfarin and DOACs users (1.20 vs. 1.32 cases per 100 person-years, p=0.27). In the IPTW weighted competing risk model, the use of DOACs was not associated with an increased risk of stroke or systemic embolism compared with warfarin users (Hazard Ratio [HR] 1.41, 95% confidence intervals [CI] 0.90-2.20). However, DOACs users had a significantly lower risk of all-cause death compared with warfarin users (HR 0.82, CI 0.74-0.91). Conclusion: Among cancer patients diagnosed with NVAF, DOACs had a similar risk for stroke or systemic embolism compared to warfarin, although DOAC use was associated with reduced risk of all-cause mortality.

A competing risk model for bond strength data analysis

2020 ◽  
Vol 36 (12) ◽  
pp. 1508-1515 ◽  
Author(s):  
Antonin Tichy ◽  
Marek Brabec ◽  
Pavel Bradna ◽  
Keiichi Hosaka ◽  
Junji Tagami
Keyword(s):  
Data Analysis ◽  
Bond Strength ◽  
Risk Model ◽  
Competing Risk ◽  
Strength Data ◽  
Competing Risk Model

A competing risk model for dependent and imperfect condition–based preventive and corrective maintenances

2014 ◽  
Vol 228 (6) ◽  
pp. 590-605 ◽  
Author(s):  
Márcio das Chagas Moura ◽  
Enrique López Droguett ◽  
Paulo Renato Alves Firmino ◽  
Ricardo José Ferreira
Keyword(s):  
Risk Model ◽  
Competing Risk ◽  
Competing Risk Model
Sign in / Sign up

Export Citation Format

Share Document